Unichem laboratories has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with stock exchanges on April 7, 2026, maintaining its regulatory compliance obligations.

Regulatory Compliance Details

The compliance certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's registrar and share transfer agent. The certificate, dated April 3, 2026, confirms adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were processed according to regulatory requirements. The registrar verified that securities were confirmed or rejected to depositories within prescribed timelines and that security certificates received for dematerialisation were properly mutilated and cancelled after due verification.

Stock Exchange Submission

Unichem Laboratories submitted the compliance certificate to both major Indian stock exchanges. The company's Head Legal & Company Secretary, Pradeep Gautam Bhandari, signed the submission letter addressed to BSE Limited and National Stock Exchange of India Limited.

This quarterly compliance certificate represents part of Unichem Laboratories' ongoing regulatory obligations as a listed pharmaceutical company, ensuring transparency in its depository and participant operations.

Unichem Laboratories Limited successfully completed its postal ballot process on 30th March 2026, with shareholders overwhelmingly approving three critical resolutions through remote e-voting. The pharmaceutical company announced the results in compliance with Regulation 44(3) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Postal Ballot Process Details

The postal ballot notice was issued on 5th February 2026, with the remote e-voting period commencing on Thursday, 26th February 2026 at 9:00 AM IST and concluding on Friday, 27th March 2026 at 5:00 PM IST. The cut-off date for determining voting eligibility was set as Friday, 20th February 2026, with a total of 24,132 shareholders registered as of that date.

Resolution Results

Resolution 1: Independent Director Appointment

Shareholders approved the appointment of Dr. Swati Patankar (DIN 06594600) as Non-Executive Independent Director for a five-year term effective 5th February 2026. This special resolution received exceptional support across all shareholder categories.

Resolution 2: Related Party Transactions with Ipca-Unichem USA

The ordinary resolution approving material related party transactions between Ipca Laboratories Limited (holding company) and Unichem Pharmaceuticals USA Inc. (wholly owned subsidiary) was passed with strong minority shareholder support.

Note: Promoter group abstained from voting due to interest in the resolution.

Resolution 3: Direct Related Party Transactions with Unichem USA

The third ordinary resolution concerning material related party transactions directly with Unichem USA, the wholly owned subsidiary, also received overwhelming approval from minority shareholders.

Scrutinizer's Validation

Alwyn D'Souza of Alwyn Jay & Co., Company Secretaries, served as the appointed scrutinizer for the postal ballot process. The scrutinizer confirmed that all procedures were conducted in compliance with Section 108, Section 110, and Section 118(10) of the Companies Act, 2013, along with applicable SEBI regulations and MCA circulars.

The e-voting facility was provided by National Securities Depository Limited (NSDL), with votes being unblocked at 5:00 PM IST on 27th March 2026 in the presence of two independent witnesses. The scrutinizer's report validated that all three resolutions were deemed passed with requisite majority.

Corporate Governance Impact

The successful completion of this postal ballot process strengthens Unichem Laboratories' governance framework through the addition of an independent director and provides regulatory approval for strategic related party transactions. The overwhelming shareholder support, particularly from minority shareholders on related party matters, demonstrates confidence in the company's business strategy and transaction transparency.

The results and scrutinizer's report are available on the company's website at www.unichemlabs.com , stock exchange websites, and NSDL's e-voting portal for stakeholder reference.